405 related articles for article (PubMed ID: 35874522)
1. A Glimpse of Inflammation and Anti-Inflammation Therapy in Diabetic Kidney Disease.
Liu C; Yang M; Li L; Luo S; Yang J; Li C; Liu H; Sun L
Front Physiol; 2022; 13():909569. PubMed ID: 35874522
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
Tang G; Li S; Zhang C; Chen H; Wang N; Feng Y
Acta Pharm Sin B; 2021 Sep; 11(9):2749-2767. PubMed ID: 34589395
[TBL] [Abstract][Full Text] [Related]
3. The mechanisms underlying Chinese medicines to treat inflammation in diabetic kidney disease.
Deng L; Shi C; Li R; Zhang Y; Wang X; Cai G; Hong Q; Chen X
J Ethnopharmacol; 2024 Jun; 333():118424. PubMed ID: 38844252
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.
Kawanami D; Takashi Y; Muta Y; Oda N; Nagata D; Takahashi H; Tanabe M
Front Pharmacol; 2021; 12():754239. PubMed ID: 34790127
[TBL] [Abstract][Full Text] [Related]
5. Oxidative Stress: A Culprit in the Progression of Diabetic Kidney Disease.
Wang N; Zhang C
Antioxidants (Basel); 2024 Apr; 13(4):. PubMed ID: 38671903
[TBL] [Abstract][Full Text] [Related]
6. Fucoidan Alleviates Renal Fibrosis in Diabetic Kidney Disease
Wang MZ; Wang J; Cao DW; Tu Y; Liu BH; Yuan CC; Li H; Fang QJ; Chen JX; Fu Y; Wan BY; Wan ZY; Wan YG; Wu GW
Front Pharmacol; 2022; 13():790937. PubMed ID: 35370636
[No Abstract] [Full Text] [Related]
7. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
Barrera-Chimal J; Jaisser F
Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
[TBL] [Abstract][Full Text] [Related]
8. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
[TBL] [Abstract][Full Text] [Related]
9. Update on diagnosis, pathophysiology, and management of diabetic kidney disease.
Sugahara M; Pak WLW; Tanaka T; Tang SCW; Nangaku M
Nephrology (Carlton); 2021 Jun; 26(6):491-500. PubMed ID: 33550672
[TBL] [Abstract][Full Text] [Related]
10. Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?
Doggrell SA
Expert Opin Pharmacother; 2021 Jul; 22(10):1253-1256. PubMed ID: 33764251
[No Abstract] [Full Text] [Related]
11. Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease.
Rroji M; Spasovski G
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540270
[TBL] [Abstract][Full Text] [Related]
12. Metformin regulates inflammation and fibrosis in diabetic kidney disease through TNC/TLR4/NF-κB/miR-155-5p inflammatory loop.
Zhou Y; Ma XY; Han JY; Yang M; Lv C; Shao Y; Wang YL; Kang JY; Wang QY
World J Diabetes; 2021 Jan; 12(1):19-46. PubMed ID: 33520106
[TBL] [Abstract][Full Text] [Related]
13. Role of Glycyrrhizin in the Reduction of Inflammation in Diabetic Kidney Disease.
Thakur V; Nargis S; Gonzalez M; Pradhan S; Terreros D; Chattopadhyay M
Nephron; 2017; 137(2):137-147. PubMed ID: 28641285
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
Zou H; Zhou B; Xu G
Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
[TBL] [Abstract][Full Text] [Related]
15. Advances in oxidative stress in pathogenesis of diabetic kidney disease and efficacy of TCM intervention.
Ma X; Ma J; Leng T; Yuan Z; Hu T; Liu Q; Shen T
Ren Fail; 2023 Dec; 45(1):2146512. PubMed ID: 36762989
[TBL] [Abstract][Full Text] [Related]
16. The role and mechanism of the gut microbiota in the development and treatment of diabetic kidney disease.
Wu X; Zhao L; Zhang Y; Li K; Yang J
Front Physiol; 2023; 14():1166685. PubMed ID: 37153213
[TBL] [Abstract][Full Text] [Related]
17. Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?
Leehey DJ
Kidney360; 2020 Apr; 1(4):292-299. PubMed ID: 35372914
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
19. New progress in drugs treatment of diabetic kidney disease.
Wang J; Xiang H; Lu Y; Wu T; Ji G
Biomed Pharmacother; 2021 Sep; 141():111918. PubMed ID: 34328095
[TBL] [Abstract][Full Text] [Related]
20. 1,25(OH)
Liu P; Li F; Xu X; Li S; Dong X; Chen L; Bai B; Wang Y; Qiu M; Dong Y
Exp Mol Pathol; 2020 Jun; 114():104434. PubMed ID: 32240615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
